Compare Liberty Energy Inc. Class A common stock (LBRT) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liberty Energy Inc. Class A common stock vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Liberty Energy Inc. Class A common stock trades at $17.97 (market cap $3.12B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Liberty Energy Inc. Class A common stock is far larger — about 3.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Liberty Energy Inc. Class A common stock pays a 1.88% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Energy Inc. Class A common stock for 6 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| LBRT | MRVI | |
|---|---|---|
Market Cap | $3.12B | $972.90M |
Volume | 2,205,743 | 4,325,710 |
Sector | Energy | Health |
52-Week High | $33.93 | $9.00 |
52-Week Low | $11.94 | $2.83 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $4.18B | $1.08B |
Dividend Yield | 1.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Liberty Energy (LBRT) trades at $19.11, up 0.68% today, with a bearish technical signal but strong analyst support. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue reached $4.01B in 2025, though net margins are thin at 2.92%. Valuation metrics like P/E of 25.82 and P/S of 0.75 suggest mixed attractiveness relative to profitability.
Outlook is cautiously optimistic given earnings momentum and a $28.38 consensus price target, but risks include margin pressure from rising costs and execution challenges in expanding into data center power. The stock's proximity to its 52-week low of $19.00 highlights downside vulnerability if Q3 results disappoint.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Liberty Energy Inc. Class A common stock
Liberty Energy provides completion services and technologies for onshore oil, natural gas, and geothermal producers in North America. It also offers distributed power and energy-storage solutions through Liberty Power Innovations.
Read more on LBRT →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
